1 | Biological: Benralizumab, Biological: Placebo to Mepolizumab (D04923) | 2件: Benralizumab Benralizumab, Mepolizumab | 2件: Mepolizumab
Mepolizumab
(D04923),
Benralizumab
💬 | 2件: IL5 IL5, IL5RA 💬 | 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 1件: 44 44 💬 |
2 | Biological: Mepolizumab, Biological: Placebo to Benralizumab (D04923) | 2件: Benralizumab Benralizumab, Mepolizumab | 2件: Mepolizumab
Mepolizumab
(D04923),
Benralizumab
💬 | 2件: IL5 IL5, IL5RA 💬 | 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 1件: 44 44 💬 |
3 | Mepolizumab (D04923) | 1件: Mepolizumab Mepolizumab | 1件: Mepolizumab
Mepolizumab
(D04923) 💬 | 1件: IL5 IL5 💬 | 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 4件: 44 44, 45, 98, 162 💬 |
4 | Mepolizumab (a-IL-5 antibody) (D04923) | 1件: Mepolizumab Mepolizumab | 1件: Mepolizumab
Mepolizumab
(D04923) 💬 | 1件: IL5 IL5 💬 | 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 1件: 162 162 💬 |
5 | Mepolizumab 100 mg (D04923) | 1件: Mepolizumab Mepolizumab | 1件: Mepolizumab
Mepolizumab
(D04923) 💬 | 1件: IL5 IL5 💬 | 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 1件: 98 98 💬 |
6 | Mepolizumab 300 mg (D04923) | 1件: Mepolizumab Mepolizumab | 1件: Mepolizumab
Mepolizumab
(D04923) 💬 | 1件: IL5 IL5 💬 | 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 1件: 98 98 💬 |
7 | SB-240563 (mepolizumab) (D04923) | 1件: Mepolizumab Mepolizumab | 1件: Mepolizumab
Mepolizumab
(D04923) 💬 | 1件: IL5 IL5 💬 | 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 2件: 44 44, 45 💬 |